US imposes 100% tariff on imported pharmaceuticals, impacting Australian exports
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals imported into the US on July 31, 2025, targeting foreign-manufactured drugs to boost domestic production and address perceived price disparities with countries like Australia. The move, exempted from a February Supreme Court ruling due to its national security justification under Section 232, threatens Australia’s $1.3–$2 billion annual pharmaceutical exports, primarily from CSL, which has heavily invested in US manufacturing to mitigate risks. While Australia’s largest exporter, CSL, may qualify for reduced tariffs or exemptions due to its US plants and plasma-derived therapies, smaller exporters face uncertainty. The US has negotiated lower tariffs (10–15%) with allies like Japan, the EU, and the UK, but Australia lacks such a deal, leaving its exports at full 100% tariff risk. Australian officials, including Health Minister Mark Butler, have firmly rejected US pressure to alter the country’s Pharmaceutical Benefits Scheme (PBS), which keeps drug prices affordable for Australians. The tariff also introduces a 120-day compliance window for large companies and 180 days for smaller firms, with incentives for relocating production to the US. Critics argue the tariffs could disrupt global supply chains and deter future investments, while supporters claim they ensure US self-sufficiency in critical medicines. The move aligns with Trump’s broader trade policies, including adjustments to steel tariffs, and comes amid political pressure over US drug affordability ahead of midterm elections.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump imposed a 100% tariff on patented pharmaceuticals manufactured outside the US on July 31, 2025, under Section 232 of the Trade Expansion Act, unaffected by the February Supreme Court ruling on 'Liberation Day' tariffs.
- Australia exported approximately $1.3–$2 billion worth of pharmaceuticals to the US in 2024–2025, with CSL (Melbourne-based) accounting for the majority of these exports.
- CSL has US manufacturing facilities in Illinois and North Carolina, with a $2.2–$2.5 billion expansion planned for completion by 2029–2031, including a $1.5 billion expansion in Illinois announced in March 2025.
- The tariff applies to patented drugs but not generic medicines, and companies moving production to the US can reduce tariffs to 20% or negotiate to zero via 'most favoured nation' pricing deals.
- Japan, South Korea, Switzerland, EU nations, and the UK have negotiated lower tariffs (10–15%) on pharmaceuticals, while Australia does not have a special tariff rate and faces the full 100% rate initially.
- The US argues the tariffs are necessary for national security, ensuring domestic production of critical drugs during emergencies or conflicts.
- Health Minister Mark Butler stated Australia would not alter its Pharmaceutical Benefits Scheme (PBS) pricing to accommodate US demands, calling the tariff 'deeply disappointing and concerning'.
- The tariff implementation timeline gives large companies 120 days and smaller firms 180 days to comply or negotiate exemptions, with new facilities required by January 2029.
Points of Difference
Details reported by only one source:
- A senior administration official mentioned Trump previously suggested the tariff could reach as high as 200% in July 2024.
- The ABC reported CSL's exports to the US were worth $1.91 billion in 2024, citing UN COMTRADE data.
- The ABC highlighted that the tariff is implemented under national security trade law, exempting it from the Supreme Court ruling on 'Liberation Day' tariffs.
- SBS quoted Health Minister Mark Butler calling the tariff 'deeply disappointing and deeply concerning' without additional context beyond the Guardian's quote.
- SBS emphasized that the tariff could slow down new medicine launches in Australia due to 'most favoured nation' rules scrutinizing PBS pricing.
- Medicines Australia stated the 'most favoured nation' rules were already hampering imports to Australia, with delays in new medicine launches due to low PBS prices.
- The article explicitly mentioned AstraZeneca had already struck specific deals with the White House to avoid tariffs.
- The Guardian noted the tariff was timed to address cost-of-living pressures in the US ahead of the November midterm elections.
- The Guardian included a direct quote from Communications Minister Anika Wells: 'The Australian PBS is not for sale.'
- The SMH reported the tariff adjustment for steel components (15% threshold for reduced tariffs) alongside the pharmaceutical tariffs, a detail not mentioned in other sources.
- The SMH quoted Trade Minister Don Farrell as saying the government would 'strongly argue for their removal' of the tariffs.
- The Age repeated the SMH's detail about the steel tariff adjustments (15% threshold) and included a direct quote from CSL: 'We’re reviewing the materials released today and will continue working with the administration to ensure access to plasma therapies.'
- The Age mentioned the tariff was timed to mark one year since Trump’s 'Liberation Day' tariffs, a phrasing not explicitly used in other sources.
Contradictions
Conflicting information between sources:
- ABC reported CSL's 2024 exports to the US as $1.91 billion, while SBS and Guardian cited $1.32 billion (COMTRADE data).
- The Guardian and SBS emphasized the tariff could force Australia to alter PBS pricing, but Health Minister Butler explicitly denied negotiating PBS fundamentals in ABC, SMH, and The Age.
- Newscomaau stated the tariff would apply to 'patented products, not generic medicines,' while ABC and Guardian did not specify this distinction explicitly.
- The SMH and The Age reported the tariff adjustment for steel components (15% threshold) as part of the same executive order, but this detail was omitted from ABC, SBS, and Guardian.
- ABC and SBS both cited a senior administration official about 'most favoured nation' deals, but Newscomaau explicitly named AstraZeneca as having already struck such a deal, which was not mentioned in other sources.
Source Articles
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....